Decheng Capital Eyes $700M Raise for Fifth Life Sciences Fund as VC Heats Up

Business concept art/iStock, Darren415

Pictured: Photo illustration of hundred dollar bill and graph/iStock, Darren415

Life sciences investment firm Decheng Capital on Monday unveiled plans for its fifth fund with a target raise of $700 million, according to an SEC filing.

Decheng has not yet disclosed the investment priorities for its fifth fund, including therapeutic areas, platform technologies or target companies, nor has it provided a specific timeline for when it expects to close its fundraising.

The investment firm—which is based in Shanghai, New York and Silicon Valley—is focused on supporting “early-stage life science companies” working on “revolutionary technologies,” according to its website. Decheng also backs “growth stage healthcare companies with strong market presence.” Since its founding in 2012, the firm has raised over $2 billion in capital and has helped fund some of the promising start-ups across the industry.  

Decheng’s portfolio includes Acelyrin,…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks